• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

万亿美元疫苗缺口。

The trillion dollar vaccine gap.

机构信息

Research and Development Center, GlaxoSmithKline (GSK), Siena, Italy.

College of the Holy Cross, Worcester, MA, USA.

出版信息

Sci Transl Med. 2022 Mar 30;14(638):eabn4342. doi: 10.1126/scitranslmed.abn4342.

DOI:10.1126/scitranslmed.abn4342
PMID:35353544
Abstract

New technologies and unprecedented public investment have transformed vaccine development and allowed fast delivery of safe and efficacious COVID-19 vaccines, mitigating the impact of the pandemic on health and the economy. A quantum change in public investment for vaccine development and widespread vaccine distribution are necessary to achieve global pandemic preparedness.

摘要

新技术和前所未有的公共投资改变了疫苗的开发方式,使安全有效的 COVID-19 疫苗得以快速推出,减轻了大流行对健康和经济的影响。为了实现全球大流行防范,必须对疫苗开发和广泛疫苗分发进行公共投资的巨大转变。

相似文献

1
The trillion dollar vaccine gap.万亿美元疫苗缺口。
Sci Transl Med. 2022 Mar 30;14(638):eabn4342. doi: 10.1126/scitranslmed.abn4342.
2
Improving pandemic preparedness through better, faster influenza vaccines.通过更好、更快的流感疫苗提高大流行防范能力。
Expert Rev Vaccines. 2021 Mar;20(3):235-242. doi: 10.1080/14760584.2021.1886931. Epub 2021 Mar 1.
3
A Pandemic Success Story: Distribution and Administration of COVID-19 Vaccines.一个大流行时期的成功故事:新冠疫苗的分发与接种
J Public Health Manag Pract. 2022;28(6):749-750. doi: 10.1097/PHH.0000000000001651.
4
COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness.COVID-19 疫苗剂量节约:提高疫苗公平性和大流行准备的策略。
Lancet Glob Health. 2022 Apr;10(4):e570-e573. doi: 10.1016/S2214-109X(22)00075-4.
5
Stakeholders' perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) - Results from a survey.利益相关者对《全球流感疫苗行动计划》(GAP)十年的看法——一项调查结果
Vaccine. 2016 Oct 26;34(45):5393-5399. doi: 10.1016/j.vaccine.2016.08.040. Epub 2016 Sep 16.
6
Social Attitude to COVID-19 and Influenza Vaccinations after the Influenza Vaccination Season and between the Second and Third COVID-19 Wave in Poland, Lithuania, and Ukraine.波兰、立陶宛和乌克兰流感季及第二波和第三波 COVID-19 疫情期间对 COVID-19 和流感疫苗接种的社会态度。
Int J Environ Res Public Health. 2022 Feb 11;19(4):2042. doi: 10.3390/ijerph19042042.
7
Future of covid-19 vaccine pricing: lessons from influenza.新冠疫苗定价的未来:流感带来的教训。
BMJ. 2021 Jun 22;373:n1467. doi: 10.1136/bmj.n1467.
8
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.mRNA 疫苗——克服 COVID-19 大流行的理想治疗策略。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2040330. doi: 10.1080/21645515.2022.2040330. Epub 2022 Mar 23.
9
[Consideration on implementation of co-administration of Seasonal Influenza and COVID-19 vaccines during pandemic in China].关于在中国大流行期间实施季节性流感疫苗与新冠疫苗联合接种的思考
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Feb 6;56(2):103-107. doi: 10.3760/cma.j.cn112150-20211203-01117.
10
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.COVID-19 疫苗与大流行:其他被忽视疾病和未来威胁的经验教训。
BMJ Glob Health. 2023 Jun;8(6). doi: 10.1136/bmjgh-2023-011883.

引用本文的文献

1
The BNT162b2 mRNA vaccine demonstrates reduced age-associated T1 support and .BNT162b2信使核糖核酸疫苗显示出与年龄相关的T1支持减少,以及……(原文此处不完整)
iScience. 2024 Sep 26;27(11):111055. doi: 10.1016/j.isci.2024.111055. eCollection 2024 Nov 15.
2
The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic.加大卫生研发投入的经济案例:从 COVID-19 大流行中吸取的教训。
Proc Natl Acad Sci U S A. 2024 Jun 25;121(26):e2321978121. doi: 10.1073/pnas.2321978121. Epub 2024 Jun 17.
3
How Scientists View Vaccine Hesitancy.
科学家如何看待疫苗犹豫现象。
Vaccines (Basel). 2023 Jul 6;11(7):1208. doi: 10.3390/vaccines11071208.
4
Factors, enablers and challenges for COVID-19 vaccine development.新冠疫苗研发的影响因素、助力因素和挑战。
BMJ Glob Health. 2023 Jun;8(6). doi: 10.1136/bmjgh-2023-011879.
5
Vaccine research and development capacity in Central and West Asia: A path toward sustainable vaccine R&D programs.中西亚地区的疫苗研发能力:实现可持续疫苗研发计划的途径。
Front Public Health. 2023 Mar 2;11:1143790. doi: 10.3389/fpubh.2023.1143790. eCollection 2023.
6
The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as a Case Study.疫苗的社会价值:以新冠疫苗为例的基于专家的概念框架和方法
Vaccines (Basel). 2023 Jan 20;11(2):234. doi: 10.3390/vaccines11020234.
7
Assessing the impact of one million COVID-19 deaths in America: economic and life expectancy losses.评估美国 100 万例 COVID-19 死亡病例的影响:经济和预期寿命损失。
Sci Rep. 2023 Feb 22;13(1):3065. doi: 10.1038/s41598-023-30077-1.
8
Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator.大流行防范与应对:超越新冠工具获取加速器。
BMJ Glob Health. 2023 Jan;8(1). doi: 10.1136/bmjgh-2022-010615.
9
Leveraging lessons learned from the COVID-19 pandemic for HIV.借鉴新冠疫情的经验教训应对艾滋病。
Commun Med (Lond). 2022 Aug 29;2:110. doi: 10.1038/s43856-022-00175-8. eCollection 2022.